Skip to main content
Erschienen in: Tumor Biology 1/2012

01.02.2012 | Research Article

Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer

verfasst von: Wenxiu Xie, Junlan Yang, Yuean Cao, Chaosheng Peng, Haoyong Ning, Fan Zhang, Junhao You

Erschienen in: Tumor Biology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to investigate the expression of Y-Box-binding protein 1 (YB-1) in breast cancer and its correlation with clinicopathological characteristics and prognosis. Paraffin sections were retrospectively collected from 239 cases of stage I–III breast cancer patients and 30 healthy females who received surgery between January 2000 and December 2004 in the Chinese People’s Liberation Army General Hospital. The protein expression of YB-1 was detected by immunohistochemistry. The expression difference between the two groups and the correlation between YB-1 expression and clinicopathological characteristics and breast cancer prognosis were analyzed. Within the breast cancer group, YB-1 was expressed in the cytoplasm in 100.0% (239/239) of cases and in the nucleus in 36.8% (88/239) of cases. Within the control group of normal breast tissue, YB-1 was expressed in the cytoplasm in 100.0% (30/30) of cases and in the nucleus in 16.7% (5/30) of cases. The expression of YB-1 in the nucleus of breast cancer cells was significantly higher than that in normal breast tissue (P = 0.029). The expression of YB-1 in the nucleus of breast cancer cells positively correlated with the Scarff–Bloom–Richardson grade (P = 0.007) and HER-2 expression (P = 0.005), negatively correlated with ER expression (P = 0.004), and was independent of the age, menstrual status, pathological type, tumor size, lymph node status, presence of thrombosis, PR expression, and EGFR expression. The 5-year disease-free survival (DFS) and overall survival (OS) of patients with positive YB-1 expression in the nucleus were significantly lower than those of patients who were negative for nuclear YB-1 expression, and the difference was statistically significant (DFS 65.9% vs. 82.1%, P = 0.000; OS 79.5% vs. 92.1%, P = 0.000). Multivariate analysis suggested that the expression of YB-1 in the nucleus is an independent prognostic factor that affects DFS and OS in breast cancer patients (DFS P = 0.015; OS P = 0.035). In conclusion, the expression of YB-1 in the nucleus is related to carcinogenesis and the development of breast cancer. Therefore, YB-1 is an important molecular marker that can be used to predict breast cancer prognosis.
Literatur
1.
Zurück zum Zitat Didier DK, Schiffenbauer J, Woulfe SL, et al. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA. 1988;85:7322–6.PubMedCrossRef Didier DK, Schiffenbauer J, Woulfe SL, et al. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA. 1988;85:7322–6.PubMedCrossRef
2.
Zurück zum Zitat Kohno K, Izumi H, Uchiumi T, et al. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25:691–8.PubMedCrossRef Kohno K, Izumi H, Uchiumi T, et al. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25:691–8.PubMedCrossRef
3.
Zurück zum Zitat Furukawa M, Uchiumi T, Nomoto M, et al. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase II alpha gene by heat shock. J Biol Chem. 1998;273:10550–5.PubMedCrossRef Furukawa M, Uchiumi T, Nomoto M, et al. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase II alpha gene by heat shock. J Biol Chem. 1998;273:10550–5.PubMedCrossRef
4.
Zurück zum Zitat Ladomery M, Sommerville J. A role for Y-box proteins in cell proliferation. Bioessays. 1995;17:9–11.PubMedCrossRef Ladomery M, Sommerville J. A role for Y-box proteins in cell proliferation. Bioessays. 1995;17:9–11.PubMedCrossRef
5.
Zurück zum Zitat Xu YL, Sun Q. Headway in resistance to endocrine therapy in breast cancer. J Thorac Dis. 2010;2:171–7. Xu YL, Sun Q. Headway in resistance to endocrine therapy in breast cancer. J Thorac Dis. 2010;2:171–7.
6.
Zurück zum Zitat Kohno K, Tanimura H, Sato S, et al. Cellular control of human multidrug resistance 1 (mdr-1) gene expression in absence and presence of gene amplification in human cancer cells. J Biol Chem. 1994;269:20503–8.PubMed Kohno K, Tanimura H, Sato S, et al. Cellular control of human multidrug resistance 1 (mdr-1) gene expression in absence and presence of gene amplification in human cancer cells. J Biol Chem. 1994;269:20503–8.PubMed
7.
Zurück zum Zitat Lv YG, Yu F, Yao Q, et al. The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2:100–10. Lv YG, Yu F, Yao Q, et al. The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2:100–10.
8.
Zurück zum Zitat En-Nia A, Yilmaz E, Klinge U, et al. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem. 2005;280:7702–11.PubMedCrossRef En-Nia A, Yilmaz E, Klinge U, et al. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem. 2005;280:7702–11.PubMedCrossRef
9.
Zurück zum Zitat Papademetriou K, Ardavanis A, Kountourakis P. Neoadjuvant therapy for locally advanced breast cancer: focus on chemotherapy and biological targeted treatments’ armamentarium. J Thorac Dis. 2010;2:160–70. Papademetriou K, Ardavanis A, Kountourakis P. Neoadjuvant therapy for locally advanced breast cancer: focus on chemotherapy and biological targeted treatments’ armamentarium. J Thorac Dis. 2010;2:160–70.
10.
Zurück zum Zitat Matsumoto K, Wolffe AP. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol. 1998;8:318–23.PubMedCrossRef Matsumoto K, Wolffe AP. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol. 1998;8:318–23.PubMedCrossRef
11.
Zurück zum Zitat Bouvet P, Wolffe AP. A role for transcription and FRGY2 in masking maternal mRNA within Xenopus oocytes. Cell. 1994;77:931–41.PubMedCrossRef Bouvet P, Wolffe AP. A role for transcription and FRGY2 in masking maternal mRNA within Xenopus oocytes. Cell. 1994;77:931–41.PubMedCrossRef
12.
Zurück zum Zitat Salvetti A, Lena A, Rossi L, et al. Characterization of DeY1, a novel Y-box gene specifically expressed in differentiating male germ cells of planarians. Gene Expr Patterns. 2002;2:195–200.PubMedCrossRef Salvetti A, Lena A, Rossi L, et al. Characterization of DeY1, a novel Y-box gene specifically expressed in differentiating male germ cells of planarians. Gene Expr Patterns. 2002;2:195–200.PubMedCrossRef
13.
Zurück zum Zitat Karlson D, Nakaminami K, Toyomasu T, et al. A cold-regulated nucleic acid-binding protein of winter wheat shares a domain with bacterial cold shock proteins. J Biol Chem. 2002;277:35248–56.PubMedCrossRef Karlson D, Nakaminami K, Toyomasu T, et al. A cold-regulated nucleic acid-binding protein of winter wheat shares a domain with bacterial cold shock proteins. J Biol Chem. 2002;277:35248–56.PubMedCrossRef
14.
Zurück zum Zitat Valadão AF, Fantappie MR, LoVerde PT, et al. Y-box binding protein from Schistosoma mansoni: interaction with DNA and RNA. Mol Biochem Parasitol. 2002;125:47–57.PubMedCrossRef Valadão AF, Fantappie MR, LoVerde PT, et al. Y-box binding protein from Schistosoma mansoni: interaction with DNA and RNA. Mol Biochem Parasitol. 2002;125:47–57.PubMedCrossRef
15.
Zurück zum Zitat Giménez-Bonafé P, Fedoruk MN, Whitmore TG, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004;59:337–49.PubMedCrossRef Giménez-Bonafé P, Fedoruk MN, Whitmore TG, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004;59:337–49.PubMedCrossRef
16.
Zurück zum Zitat Shibahara K, Sugio K, Osaki T, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001;7:3151–5.PubMed Shibahara K, Sugio K, Osaki T, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001;7:3151–5.PubMed
17.
Zurück zum Zitat Shibao K, Takano H, Nakayama Y, et al. Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer. 1999;83:732–7.PubMedCrossRef Shibao K, Takano H, Nakayama Y, et al. Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer. 1999;83:732–7.PubMedCrossRef
18.
Zurück zum Zitat Kamura T, Yahata H, Amada S, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer. 1999;85:2450–4.PubMedCrossRef Kamura T, Yahata H, Amada S, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer. 1999;85:2450–4.PubMedCrossRef
19.
Zurück zum Zitat Dahl E, En-Nia A, Wiesmann F, et al. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009;9:410.PubMedCrossRef Dahl E, En-Nia A, Wiesmann F, et al. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009;9:410.PubMedCrossRef
20.
Zurück zum Zitat Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 1997;417:390–4.PubMedCrossRef Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 1997;417:390–4.PubMedCrossRef
21.
Zurück zum Zitat Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 1996;56:4224–8.PubMed Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 1996;56:4224–8.PubMed
22.
Zurück zum Zitat Ise T, Nagatani G, Imamura T, et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res. 1999;59:342–6.PubMed Ise T, Nagatani G, Imamura T, et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res. 1999;59:342–6.PubMed
23.
Zurück zum Zitat Bargou RC, Jürchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3:447–50.PubMedCrossRef Bargou RC, Jürchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3:447–50.PubMedCrossRef
24.
Zurück zum Zitat Oda Y, Sakamoto A, Shinohara N, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res. 1998;4:2273–7.PubMed Oda Y, Sakamoto A, Shinohara N, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res. 1998;4:2273–7.PubMed
25.
Zurück zum Zitat Jurchott K, Bergmann S, Stein U, et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem. 2003;278:27988–96.PubMedCrossRef Jurchott K, Bergmann S, Stein U, et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem. 2003;278:27988–96.PubMedCrossRef
26.
Zurück zum Zitat Wu J, Lee C, Yokom D, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006;66:4872–9.PubMedCrossRef Wu J, Lee C, Yokom D, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006;66:4872–9.PubMedCrossRef
27.
Zurück zum Zitat Stratford AL, Habibi G, Astanehe A, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res. 2007;9:R61.PubMedCrossRef Stratford AL, Habibi G, Astanehe A, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res. 2007;9:R61.PubMedCrossRef
28.
Zurück zum Zitat Berquin IM, Pang B, Dziubinski ML, et al. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene. 2005;24:3177–86.PubMedCrossRef Berquin IM, Pang B, Dziubinski ML, et al. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene. 2005;24:3177–86.PubMedCrossRef
29.
Zurück zum Zitat Schittek B, Psenner K, Sauer B, et al. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer. 2007;120:2110–8.PubMedCrossRef Schittek B, Psenner K, Sauer B, et al. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer. 2007;120:2110–8.PubMedCrossRef
30.
Zurück zum Zitat Oda Y, Ohishi Y, Basaki Y, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci. 2007;98:1020–6.PubMedCrossRef Oda Y, Ohishi Y, Basaki Y, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci. 2007;98:1020–6.PubMedCrossRef
31.
Zurück zum Zitat Fujii T, Kawahara A, Basaki Y, et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 2008;68:1504–12.PubMedCrossRef Fujii T, Kawahara A, Basaki Y, et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 2008;68:1504–12.PubMedCrossRef
Metadaten
Titel
Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer
verfasst von
Wenxiu Xie
Junlan Yang
Yuean Cao
Chaosheng Peng
Haoyong Ning
Fan Zhang
Junhao You
Publikationsdatum
01.02.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0246-6

Weitere Artikel der Ausgabe 1/2012

Tumor Biology 1/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.